NOV 18, 2021
Genelux Announces Exclusive Out-Licensing Agreement with ELIAS Animal Health for V-VET1, a Proprietary Oncolytic Vaccinia Virus Treatment for Pets with Various Cancers
V-VET1, a clinical-stage animal health-specific product candidate, is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis)